| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.18 | 0.0005 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.18 | 0.0006 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.18 | 0.0006 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0007 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0007 |